Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Acromegaly and Gigantism Drugs Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 605131
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Acromegaly and Gigantism Drugs Market 2018-2022
Published: February 9, 2018 Content info: 100 Pages
Description

About Acromegaly and Gigantism Drugs

The acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.

Technavio's analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Ipsen
  • Novartis
  • Pfizer

Market driver

  • Strong pipeline
  • For a full, detailed list, view our report

Market challenge

  • Difficulty in diagnosis
  • For a full, detailed list, view our report

Market trend

  • Growing popularity of drugs over surgeries
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR20504

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS

  • Segmentation by drug class
  • Comparison by drug class
  • Somatostatin analogs - Market size and forecast 2017-2022
  • GH receptor antagonists - Market size and forecast 2017-2022
  • Dopamine agonists - Market size and forecast 2017-2022
  • Recombinant human IGF-1 - Market size and forecast 2017-2022
  • Market opportunity by product

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • Growing popularity of drugs over surgeries
  • Focus on long-acting novel formulations

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ipsen
  • Novartis
  • Pfizer

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global acromegaly and gigantism drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
  • Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase
  • Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market
  • Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
  • Exhibit 21: Comparison by drug class
  • Exhibit 22: Somatostatin analogs - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: Somatostatin analogs - YoY growth 2018-2022 (%)
  • Exhibit 24: GH receptor antagonists - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: GH receptor antagonists - YoY growth 2018-2022 (%)
  • Exhibit 26: Dopamine agonists - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 27: Dopamine agonists - YoY growth 2018-2022 (%)
  • Exhibit 28: Recombinant human IGF-1 - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 29: Recombinant human IGF-1 - YoY growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: Americas - YoY growth 2018-2022 (%)
  • Exhibit 36: Top three countries in Americas
  • Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: EMEA - YoY growth 2018-2022 (%)
  • Exhibit 39: Top three countries in EMEA
  • Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 41: APAC - YoY growth 2018-2022 (%)
  • Exhibit 42: Top three countries in APAC
  • Exhibit 43: Market opportunity
  • Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Ipsen - Vendor overview
  • Exhibit 51: Ipsen - Business segments
  • Exhibit 52: Ipsen - Organizational developments
  • Exhibit 53: Ipsen - Geographic focus
  • Exhibit 54: Ipsen - Segment focus
  • Exhibit 55: Ipsen - Key offerings
  • Exhibit 56: Ipsen- Key customers
  • Exhibit 57: Novartis - Vendor overview
  • Exhibit 58: Novartis - Business segments
  • Exhibit 59: Novartis - Organizational developments
  • Exhibit 60: Novartis - Geographic focus
  • Exhibit 61: Novartis - Segment focus
  • Exhibit 62: Novartis - Key offerings
  • Exhibit 63: Pfizer - Vendor overview
  • Exhibit 64: Pfizer - Business segments
  • Exhibit 65: Pfizer - Organizational developments
  • Exhibit 66: Pfizer - Geographic focus
  • Exhibit 67: Pfizer - Segment focus
  • Exhibit 68: Pfizer - Key offerings
  • Exhibit 69: Pfizer - Key customers
Back to Top